AU2139097A - Methods of treating or preventing sleep apnea - Google Patents

Methods of treating or preventing sleep apnea

Info

Publication number
AU2139097A
AU2139097A AU21390/97A AU2139097A AU2139097A AU 2139097 A AU2139097 A AU 2139097A AU 21390/97 A AU21390/97 A AU 21390/97A AU 2139097 A AU2139097 A AU 2139097A AU 2139097 A AU2139097 A AU 2139097A
Authority
AU
Australia
Prior art keywords
treating
methods
sleep apnea
preventing sleep
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21390/97A
Inventor
Bruce D. Gitter
Smriti Iyengar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2139097A publication Critical patent/AU2139097A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU21390/97A 1996-03-01 1997-02-26 Methods of treating or preventing sleep apnea Abandoned AU2139097A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1266596P 1996-03-01 1996-03-01
US60012665 1996-03-01
PCT/US1997/003113 WO1997031635A1 (en) 1996-03-01 1997-02-26 Methods of treating or preventing sleep apnea

Publications (1)

Publication Number Publication Date
AU2139097A true AU2139097A (en) 1997-09-16

Family

ID=21756104

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21390/97A Abandoned AU2139097A (en) 1996-03-01 1997-02-26 Methods of treating or preventing sleep apnea

Country Status (2)

Country Link
AU (1) AU2139097A (en)
WO (1) WO1997031635A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050398A2 (en) * 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
US7271180B2 (en) 2001-01-23 2007-09-18 Wyeth 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
KR20050029209A (en) 2002-07-15 2005-03-24 미리어드 제네틱스, 인크. Compounds, compositions, and methods employing same
US7094790B2 (en) 2003-05-07 2006-08-22 Abbott Laboratories Fused bicyclic-substituted amines as histamine-3 receptor ligands
ES2574253T3 (en) 2009-12-18 2016-06-16 Mitsubishi Tanabe Pharma Corporation New antiplatelet agent
ES2616238T3 (en) 2010-10-06 2017-06-12 Glaxosmithkline Llc, Corporation Service Company Benzimidazole derivatives as PI3 kinase inhibitors
JP6001049B2 (en) 2011-03-31 2016-10-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH Substituted benzimidazoles as MPS-1 kinase inhibitors
MX2021011775A (en) 2017-04-26 2023-01-10 Basilea Pharm Int Ag Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea

Also Published As

Publication number Publication date
WO1997031635A1 (en) 1997-09-04

Similar Documents

Publication Publication Date Title
KR20010006384A (en) Method and composition for treating sleep apnea
AU4678897A (en) Humidifier sleep apnea treatment apparatus
AU7538398A (en) Emulsion for well and formation treatment
ZA965088B (en) Methods of preventing or treating allergles
AU7264298A (en) Apparatus and method for the reduction of snoring
AU7905894A (en) Treatment of poultry
AU2058697A (en) Treatment of sleep disorders
AU2207897A (en) Methods of treating or preventing interstitial cystitis
HRP970224A2 (en) TREATMENT OF ASTHMA WITH TNFR-Ig
AU2243897A (en) Methods of treating or preventing pain or nociception
AU1977497A (en) Methods of treating or preventing sleep apnea
AU4027097A (en) Method of treatment
PL331283A1 (en) Preparation for treating and/or preventing stupefaction
AUPM836794A0 (en) Improved method and composition for the treatment of ulcers
HU9900436D0 (en) Installation and method for the treatment of wine-production efilvents
AU4402497A (en) Methods and means for the treatment of malignancies
AUPO101996A0 (en) Devices and methods for treating sleep apnoea
AU6423996A (en) An oral appliance for treating sleep apnea
AU5708598A (en) Curved surgical needles and method of making the same
AUPN925096A0 (en) Methods of treatment
AU2359197A (en) Method of treating wood and the wood
AU2071497A (en) Methods of treating or preventing interstitial cystitis
AUPN504195A0 (en) An oral appliance for treating sleep apnea
AUPO019296A0 (en) Treatment of asthma
AU3597695A (en) Improved method and composition for the treatment of ulcers